Lisata says Kuva Labs launches tender offer at USD 4 per share plus CVR

Lisata Therapeutics, Inc.

LSTA

0.00

Kuva Labs unit Kuva Acquisition began a tender offer for all Lisata Therapeutics shares under a March 6, 2026 merger agreement.
Consideration set at USD 4 per share in cash at closing, with a non-tradeable CVR for up to USD 3 per share.
CVR milestones tied to a GBM Phase 2a enrollment event worth USD 1.25, plus an NDA filing or acceptance worth USD 1.75.
Offer scheduled to expire at 11:59 p.m. New York time on July 10, 2026, unless extended.
Closing targeted for Q3 2026; Kuva disclosed it lacks committed financing, with funding expected from debt or equity sources.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100800PRIMZONEFULLFEED9734711) on June 10, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.